Brand Name
Briviact
Generic Name
Brivaracetam
View Brand Information FDA approval date: May 12, 2016
Form: Injection, Tablet, Solution
What is Briviact (Brivaracetam)?
BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY
Summary: The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy
Summary: The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.